KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

NovoCure (NVCR) Leases (2019 - 2025)

NovoCure's Leases history spans 7 years, with the latest figure at $47.3 million for Q4 2025.

  • For Q4 2025, Leases rose 74.51% year-over-year to $47.3 million; the TTM value through Dec 2025 reached $47.3 million, up 74.51%, while the annual FY2025 figure was $47.3 million, 74.51% up from the prior year.
  • Leases for Q4 2025 was $47.3 million at NovoCure, down from $48.4 million in the prior quarter.
  • Across five years, Leases topped out at $48.5 million in Q1 2025 and bottomed at $16.5 million in Q3 2021.
  • The 5-year median for Leases is $26.7 million (2023), against an average of $28.8 million.
  • The largest annual shift saw Leases dropped 22.15% in 2024 before it surged 74.51% in 2025.
  • A 5-year view of Leases shows it stood at $18.3 million in 2021, then grew by 29.17% to $23.6 million in 2022, then surged by 47.63% to $34.8 million in 2023, then dropped by 22.15% to $27.1 million in 2024, then soared by 74.51% to $47.3 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Leases are $47.3 million (Q4 2025), $48.4 million (Q3 2025), and $48.1 million (Q2 2025).